AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19674354
Drug: Nebulized 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 3% hypertonic saline solution and salbutamol
Trial: 19674354
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (4.0 mL normal (0.9%) saline with 2.5 mg salbutamol)
Trial: 15687232
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy followed by purged autologous stem-cell transplantation
Trial: 15687232
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and interferon (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon)
Trial: 12297768
Drug: Balloon-occluded endoscopic
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon-occluded endoscopic injection sclerotherapy (BO-EIS)
Trial: 8758250
Drug: Ifosfamide (IFO)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFO) administered as 6-9 g/m2 over 15 days, repeated every 3 weeks for up to 16 courses, either as a continuous 72 h infusion or as three bolus doses of 3 g/m2 on consecutive days.
Trial: 8758250
Drug: Ifosfamide (IFO)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFO) administration with changes in metabolism measured during early and late courses.
Trial: 1883969
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (100 U/kg thrice weekly for 6 weeks, then 50 to 150 U/kg thrice weekly for 6 weeks)
Trial: 30225786
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity prescription (PPA)
Trial: 28887907
Drug: WBB beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBB beverage (25 g freeze dried WBB powder)
Trial: 22249353
Drug: Tailored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored treatment strategy using the Multiplate analyzer
Trial: 18046053
Drug: Red Bull
RxNorm normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Bull energy drink (2 mg/kg body mass of caffeine)
Trial: 8789567
Drug: Alcohol (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.2 g alcohol.kg‐1 body mass)
Trial: 6803692
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day for 4 months)
Trial: 26715522
Drug: Iron-treated group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-treated group (50 mg elemental iron/daily)
Trial: 11386492
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/day)
Trial: 15195691
Drug: Nicardipine solution
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine solution (20 mg)
Trial: 2871952
Drug: Atropine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1.2 mg, i.v.)
Trial: 2871952
Drug: Metoclopramide (MCP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP, 10 mg, i.v.)
Trial: 25601942
Drug: SA-14-14-2 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA-14-14-2 (single dose)
Trial: 25601942
Drug: JENVAC (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JENVAC (single dose)
Trial: 25601942
Drug: JENVAC (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JENVAC (2 doses)
Trial: 11346336
Drug: Crossover from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover from 6.5 mg/m(2) per day to higher doses
Trial: 11346336
Drug: 300 mg/m(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/m(2) per day
Trial: 795700
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (5 mg, sublingual)
Trial: 1657221
Drug: Intravenous methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylphenidate
Trial: 27218476
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration EtOH (targeted BrAC = 0.100 g/dl)
Trial: 19721480
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon and ribavirin treatment
Trial: 18444168
Drug: Lycopene supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene supplementation (30 mg/day for 2 months)
Trial: 16006090
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron saccharate Venofer (5 mg/kg injection on day 1)
Trial: 11049243
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ambroxol administered)
Trial: 6712466
Drug: Dexamethasone sodium
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate (6 mg/kg) over 48 hours
Trial: 29947107
Drug: Concurrent aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent aerobic and resistance exercise (CEX)
Trial: 16300166
Drug: EMD 87
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 87 580 (50 mg once daily) in patients with renal dysfunction (Group 2)
Trial: 16300166
Drug: EMD 87
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 87 580 (100 mg twice daily) in patients with normal renal function (Group 1)
Trial: 16300166
Drug: EMD 87
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 87 580 (50 mg dose) in patients with renal dysfunction (Group 2)
Trial: 16300166
Drug: EMD 87
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 87 580 (50 mg dose) in patients with normal renal function (Group 1)
Trial: 18987098
Drug: Candesartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (target dose 32 mg once daily, mean dose 24 mg)
Trial: 1555751
Drug: Ursodeoxycholate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholate (600 mg/day)
Trial: 4006240
Drug: Timolol (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (10-20 mg/d) for 6 weeks
Trial: 4006240
Drug: Methyldopa (250-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (250-500 mg/d) for 6 weeks
Trial: 16545251
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (3500 IU/d of bemiparin) subcutaneously for 6 months
Trial: 26772193
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy (in patients not receiving antibiotics)
Trial: 14724157
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy
Trial: 507256
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of bivalent split virus vaccine (A/New Jersey/76 and A/Victoria/75) intradermally
Trial: 507256
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of bivalent split virus vaccine (A/New Jersey/76 and A/Victoria/75) subcutaneously
Trial: 30297351
Drug: Marine protein
RxNorm normalized name: Ascorbic Acid/Biotin/Coenzyme Q10/Grape Seed Extract/Hydrated Silica/Marine Protein/Mucopolysaccharides/Selenium/Vitamin A/Vitamin D/Vitamin E/Zinc 62 MG-50 MCG-5 MG-15 MG-60 MG-83 MCG-2417 IU-51 IU-25.5 IU-1.8 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine protein hydrolysate (MPH) 3 g per day for 12 months
Trial: 17978591
Drug: Carvedilol 6.25
RxNorm normalized name: carvedilol 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25 to 25 mg bid
Trial: 11933177
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by radiotherapy (CT + RT)
Trial: 12841537
Drug: Insulin (I)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (I)
Trial: 8150016
Drug: Standard Schwarz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Schwarz (SW) measles vaccine
Trial: 29992584
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of intravenous drug use (IVDU)
Trial: 22042277
Drug: PEG-L-asparaginase (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-L-asparaginase (2500 IU/m/dose intramuscularly on days 1 and 15)
Trial: 22042277
Drug: Native E.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native E. coli asparaginase (10,000 IU/m/dose intramuscularly on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26)
Trial: 16409194
Drug: Grass allergen
RxNorm normalized name: orchardgrass allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass allergen tablets (75,000 SQ‐T)
Trial: 14531956
Drug: Disease-modifying antirheumatic
RxNorm normalized name: ANTIRHEUMATICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying antirheumatic drugs (DMARDs), specific types and dosages not mentioned, focus on effective treatment for RA.
Trial: 7997902
Drug: promethazine 0.5
RxNorm normalized name: PROMETHAZINE 0.5MG/ML/NACL INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine 0.5 mg/kg
Trial: 7997902
Drug: metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 0.2 mg/kg
Trial: 3395401
Drug: Vadocaine hydrochloride
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vadocaine hydrochloride 15 mg
Trial: 3395401
Drug: Vadocaine hydrochloride
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vadocaine hydrochloride (5, 10, 15, 20, 30, 50 mg)
Trial: 31869817
Drug: TMR® FAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMR® FAB 6-treatment protocol
Trial: 29117576
Drug: AMH measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMH measured at end of chemotherapy
Trial: 24626819
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d of algal docosahexaenoic acid (DHA)
Trial: 16115731
Drug: LRRK 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRRK 2 G 2019 S and I 2020 T mutations evaluation in healthy controls
Trial: 12106929
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion at increasing doses in the infarct-related artery (IRA)
Trial: 10442370
Drug: UFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT plus oral calcium folinate combined with epirubicin and cyclophosphamide
Trial: 10442370
Drug: Continuous-infusion 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion 5-fluorouracil (5-FU)
Trial: 25647628
Drug: Sunitinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib administered at 6 p.m.
Trial: 25647628
Drug: Sunitinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib administered at 8 a.m.
Trial: 25647628
Drug: Sunitinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib administered at 4 a.m. and 4 p.m.
Trial: 25647628
Drug: Sunitinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib administered at different times (8 a.m., 1 p.m., 6 p.m.).
Trial: 24369195
Drug: Fosaprepitant (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (150 mg IV on day 1)
Trial: 12765889
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) clonidine 150 microg
Trial: 3567018
Drug: Carbamazepine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400 mg) in young volunteers
Trial: 3567018
Drug: Carbamazepine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400 mg) in elderly volunteers
Trial: 29856114
Drug: Insulin dosing
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dosing for both protein and carbohydrate
Trial: 24752448
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (BCG and electromotive mitomycin)
Trial: 24752448
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy vs BCG alone
Trial: 22585285
Drug: Tolvaptan 30
RxNorm normalized name: tolvaptan 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 30 mg under fasting conditions
Trial: 15764724
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone (3,000 microg/hour) administered through a metered‐dose inhaler and spacer at 10‐minute intervals for 3 hours
Trial: 7846337
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (500 mg)
Trial: 10487192
Drug: Gabapentin (GBP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP), 2,400 mg/day
Trial: 10487192
Drug: Carbamazepine (CBZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ), mean 731 mg/day
Trial: 1912554
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human erythropoietin (rhEPO) at a dose of 1,200 to 1,600 U/kg intravenously (IV) twice weekly
Trial: 27180954
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) 500 mg t.i.d.
Trial: 27180954
Drug: Methylcobalamin (MC)
RxNorm normalized name: MC-16
DrugBank: MC-16 (DB18005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin (MC) 0.5 mg t.i.d.
Trial: 9154674
Drug: Thymostimulin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (1 mg/kg day for the 1st week followed by once a week for 6 months)
Trial: 9154674
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for COPD (Control group)
Trial: 20493183
Drug: Mud bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud bath treatments combined with hydropinotherapy (Group A)
Trial: 20493183
Drug: Mud bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud bath treatments without hydropinotherapy (Group B)
Trial: 20493183
Drug: No spa
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 25 g in 100 mL TOPICAL LIQUID [Stefano Spazio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No spa therapies (Group C)
Trial: 10425301
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (PVM) consisting of 2 cycles of the same chemotherapy in 4-week intervals.
Trial: 111275
Drug: Clorgyline (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorgyline (selective MAO‐A inhibitor)
Trial: 111275
Drug: Pargyline (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pargyline (selective MAO‐B inhibitor)
Trial: 19228209
Drug: Delayed post‐space
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed post‐space preparation (5 days later) with Resilon/Epiphany
Trial: 31703648
Drug: Per‐oral carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per‐oral carbohydrate load (preOp™) 18 and 2‐4 h before surgery (n=26)
Trial: 31703648
Drug: Per‐oral carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per‐oral carbohydrate load (preOp™)
Trial: 28322474
Drug: Ixekizumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80 mg subcutaneous every 2 or 4 weeks after a 160 mg starting dose)
Trial: 21839402
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg biweekly)
Trial: 25377269
Drug: Ghrelin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin administration (3 μg/kg, twice a day)
Trial: 25377269
Drug: Ghrelin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin administration (both regimens)
Trial: 24088225
Drug: Lovastatin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (200 mg for 4 days)
Trial: 21107813
Drug: Alpha-blocker monotherapy
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker monotherapy
Trial: 21107813
Drug: Extracorporeal magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal magnetic innervations (ExMI) monotherapy
Trial: 21107813
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (alpha-blocker + ExMI)
Trial: 17192497
Drug: Intranasal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketorolac
Trial: 12076871
Drug: Daily high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily high dose interferon (IFN) for 6 weeks followed by standard therapy of 3 million units three times a week in combination with ribavirin for 42 weeks
Trial: 10078675
Drug: Midazolam 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1.0 mg intravenously and 2.0 mg intravenously
Trial: 10078675
Drug: Diazepam emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam emulsion 2.0 mg intravenously and 5.0 mg intravenously
Trial: 7216144
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Trial: 26703193
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic Acid (IV TXA)
Trial: 20196388
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme (ACE) inhibitors for all patients
Trial: 20196388
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment protocol for severe HSP nephritis
Trial: 17454701
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (nortriptyline hydrochloride)
Trial: 8088068
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) starting dose 5 mg/kg
Trial: 2760256
Drug: Diltiazem (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (mean daily dose 360 mg)
Trial: 2760256
Drug: Combination diltiazem-nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination diltiazem-nifedipine therapy (mean daily dose 55 mg of nifedipine, 360 mg of diltiazem)
Trial: 31207178
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of individual components (ertugliflozin with metformin)
Trial: 1779539
Drug: Directed transport
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed transport of antibiotics in autologous blood shadows
Trial: 28398490
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Trial: 27593381
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injected (1.5 ml)
Trial: 27593381
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injected (1.5 ml)
Trial: 25122597
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid injection
Trial: 22645323
Drug: Steroid avoidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid avoidance
Trial: 18940487
Drug: 1 IA
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 IA infiltration of sodium hyaluronate (1 mL)